These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32182396)

  • 1. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
    Zhang Y; Zhu H; Layritz F; Luo H; Wohlfahrt T; Chen CW; Soare A; Bergmann C; Ramming A; Groeber F; Reuter C; Fornasini G; Soukhareva N; Schreiber B; Ramamurthy S; Amann K; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
    Hasegawa T; Utsunomiya A; Chino T; Kasamatsu H; Shimizu T; Matsushita T; Obara T; Ishii N; Ogasawara H; Ikeda W; Imai T; Oyama N; Hasegawa M
    Arthritis Res Ther; 2024 May; 26(1):94. PubMed ID: 38702742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis.
    Grönberg C; Rattik S; Tran-Manh C; Zhou X; Rius Rigau A; Li YN; Györfi AH; Dickel N; Kunz M; Kreuter A; Matei EA; Zhu H; Skoog P; Liberg D; Distler JH; Trinh-Minh T
    Ann Rheum Dis; 2024 Aug; 83(9):1156-1168. PubMed ID: 38594058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
    Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
    Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.
    Mor A; Segal Salto M; Katav A; Barashi N; Edelshtein V; Manetti M; Levi Y; George J; Matucci-Cerinic M
    Ann Rheum Dis; 2019 Sep; 78(9):1260-1268. PubMed ID: 31129606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of 5-aminolevulinic acid and iron prevents skin fibrosis in murine sclerodermatous graft-versus-host disease.
    Liu C; Yang X; Zhu P; Fujino M; Ito H; Takahashi K; Nakajima M; Tanaka T; Wang J; Zhuang J; Zou H; Li XK
    Exp Dermatol; 2018 Oct; 27(10):1104-1111. PubMed ID: 29978518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma.
    Tsujino K; Reed NI; Atakilit A; Ren X; Sheppard D
    Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L22-L31. PubMed ID: 27864286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiomyopathy in murine models of systemic sclerosis.
    Venalis P; Kumánovics G; Schulze-Koops H; Distler A; Dees C; Zerr P; Palumbo-Zerr K; Czirják L; Mackevic Z; Lundberg IE; Distler O; Schett G; Distler JH
    Arthritis Rheumatol; 2015 Feb; 67(2):508-16. PubMed ID: 25371068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.
    Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Miura S; Toyama T; Takahashi T; Ichimura Y; Yoshizaki A; Trojanowska M; Sato S
    J Invest Dermatol; 2017 Mar; 137(3):631-640. PubMed ID: 27777101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
    Zhang Y; McCormick LL; Gilliam AC
    J Invest Dermatol; 2003 Oct; 121(4):713-9. PubMed ID: 14632186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
    McCormick LL; Zhang Y; Tootell E; Gilliam AC
    J Immunol; 1999 Nov; 163(10):5693-9. PubMed ID: 10553100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
    Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis.
    Bagnato G; Bitto A; Pizzino G; Irrera N; Sangari D; Cinquegrani M; Roberts WN; Matucci Cerinic M; Squadrito F; Altavilla D; Bagnato G; Saitta A
    Rheumatology (Oxford); 2013 Aug; 52(8):1377-86. PubMed ID: 23620550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.
    Marut W; Kavian N; Servettaz A; Hua-Huy T; Nicco C; Chéreau C; Weill B; Dinh-Xuan AT; Batteux F
    Arthritis Rheum; 2013 May; 65(5):1367-77. PubMed ID: 23335130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COA-Cl prevented TGF-β1-induced CTGF expression by Akt dephosphorylation in normal human dermal fibroblasts, and it attenuated skin fibrosis in mice models of systemic sclerosis.
    Nakai K; Karita S; Igarashi J; Tsukamoto I; Hirano K; Kubota Y
    J Dermatol Sci; 2019 Apr; 94(1):205-212. PubMed ID: 30954335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.